Cargando…

Alternative metrics for characterizing longer-term clinical outcomes in difficult-to-treat depression: I. Association with change in quality of life

BACKGROUND: In difficult-to-treat depression (DTD) the outcome metrics historically used to evaluate treatment effectiveness may be suboptimal. Metrics based on remission status and on single end-point (SEP) assessment may be problematic given infrequent symptom remission, temporal instability, and...

Descripción completa

Detalles Bibliográficos
Autores principales: Sackeim, Harold A., Rush, A. John, Greco, Teresa, Jiang, Mei, Badejo, Sarah, Bunker, Mark T., Aaronson, Scott T., Conway, Charles R., Demyttenaere, Koen, Young, Allan H., McAllister-Williams, R. Hamish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cambridge University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600942/
https://www.ncbi.nlm.nih.gov/pubmed/36601813
http://dx.doi.org/10.1017/S0033291722003798
_version_ 1785126093957627904
author Sackeim, Harold A.
Rush, A. John
Greco, Teresa
Jiang, Mei
Badejo, Sarah
Bunker, Mark T.
Aaronson, Scott T.
Conway, Charles R.
Demyttenaere, Koen
Young, Allan H.
McAllister-Williams, R. Hamish
author_facet Sackeim, Harold A.
Rush, A. John
Greco, Teresa
Jiang, Mei
Badejo, Sarah
Bunker, Mark T.
Aaronson, Scott T.
Conway, Charles R.
Demyttenaere, Koen
Young, Allan H.
McAllister-Williams, R. Hamish
author_sort Sackeim, Harold A.
collection PubMed
description BACKGROUND: In difficult-to-treat depression (DTD) the outcome metrics historically used to evaluate treatment effectiveness may be suboptimal. Metrics based on remission status and on single end-point (SEP) assessment may be problematic given infrequent symptom remission, temporal instability, and poor durability of benefit in DTD. METHODS: Self-report and clinician assessment of depression symptom severity were regularly obtained over a 2-year period in a chronic and highly treatment-resistant registry sample (N = 406) receiving treatment as usual, with or without vagus nerve stimulation. Twenty alternative metrics for characterizing symptomatic improvement were evaluated, contrasting SEP metrics with integrative (INT) metrics that aggregated information over time. Metrics were compared in effect size and discriminating power when contrasting groups that did (N = 153) and did not (N = 253) achieve a threshold level of improvement in end-point quality-of-life (QoL) scores, and in their association with continuous QoL scores. RESULTS: Metrics based on remission status had smaller effect size and poorer discrimination of the binary QoL outcome and weaker associations with the continuous end-point QoL scores than metrics based on partial response or response. The metrics with the strongest performance characteristics were the SEP measure of percentage change in symptom severity and the INT metric quantifying the proportion of the observation period in partial response or better. Both metrics contributed independent variance when predicting end-point QoL scores. CONCLUSIONS: Revision is needed in the metrics used to quantify symptomatic change in DTD with consideration of INT time-based measures as primary or secondary outcomes. Metrics based on remission status may not be useful.
format Online
Article
Text
id pubmed-10600942
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cambridge University Press
record_format MEDLINE/PubMed
spelling pubmed-106009422023-10-27 Alternative metrics for characterizing longer-term clinical outcomes in difficult-to-treat depression: I. Association with change in quality of life Sackeim, Harold A. Rush, A. John Greco, Teresa Jiang, Mei Badejo, Sarah Bunker, Mark T. Aaronson, Scott T. Conway, Charles R. Demyttenaere, Koen Young, Allan H. McAllister-Williams, R. Hamish Psychol Med Original Article BACKGROUND: In difficult-to-treat depression (DTD) the outcome metrics historically used to evaluate treatment effectiveness may be suboptimal. Metrics based on remission status and on single end-point (SEP) assessment may be problematic given infrequent symptom remission, temporal instability, and poor durability of benefit in DTD. METHODS: Self-report and clinician assessment of depression symptom severity were regularly obtained over a 2-year period in a chronic and highly treatment-resistant registry sample (N = 406) receiving treatment as usual, with or without vagus nerve stimulation. Twenty alternative metrics for characterizing symptomatic improvement were evaluated, contrasting SEP metrics with integrative (INT) metrics that aggregated information over time. Metrics were compared in effect size and discriminating power when contrasting groups that did (N = 153) and did not (N = 253) achieve a threshold level of improvement in end-point quality-of-life (QoL) scores, and in their association with continuous QoL scores. RESULTS: Metrics based on remission status had smaller effect size and poorer discrimination of the binary QoL outcome and weaker associations with the continuous end-point QoL scores than metrics based on partial response or response. The metrics with the strongest performance characteristics were the SEP measure of percentage change in symptom severity and the INT metric quantifying the proportion of the observation period in partial response or better. Both metrics contributed independent variance when predicting end-point QoL scores. CONCLUSIONS: Revision is needed in the metrics used to quantify symptomatic change in DTD with consideration of INT time-based measures as primary or secondary outcomes. Metrics based on remission status may not be useful. Cambridge University Press 2023-10 2023-01-05 /pmc/articles/PMC10600942/ /pubmed/36601813 http://dx.doi.org/10.1017/S0033291722003798 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution and reproduction, provided the original article is properly cited.
spellingShingle Original Article
Sackeim, Harold A.
Rush, A. John
Greco, Teresa
Jiang, Mei
Badejo, Sarah
Bunker, Mark T.
Aaronson, Scott T.
Conway, Charles R.
Demyttenaere, Koen
Young, Allan H.
McAllister-Williams, R. Hamish
Alternative metrics for characterizing longer-term clinical outcomes in difficult-to-treat depression: I. Association with change in quality of life
title Alternative metrics for characterizing longer-term clinical outcomes in difficult-to-treat depression: I. Association with change in quality of life
title_full Alternative metrics for characterizing longer-term clinical outcomes in difficult-to-treat depression: I. Association with change in quality of life
title_fullStr Alternative metrics for characterizing longer-term clinical outcomes in difficult-to-treat depression: I. Association with change in quality of life
title_full_unstemmed Alternative metrics for characterizing longer-term clinical outcomes in difficult-to-treat depression: I. Association with change in quality of life
title_short Alternative metrics for characterizing longer-term clinical outcomes in difficult-to-treat depression: I. Association with change in quality of life
title_sort alternative metrics for characterizing longer-term clinical outcomes in difficult-to-treat depression: i. association with change in quality of life
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10600942/
https://www.ncbi.nlm.nih.gov/pubmed/36601813
http://dx.doi.org/10.1017/S0033291722003798
work_keys_str_mv AT sackeimharolda alternativemetricsforcharacterizinglongertermclinicaloutcomesindifficulttotreatdepressioniassociationwithchangeinqualityoflife
AT rushajohn alternativemetricsforcharacterizinglongertermclinicaloutcomesindifficulttotreatdepressioniassociationwithchangeinqualityoflife
AT grecoteresa alternativemetricsforcharacterizinglongertermclinicaloutcomesindifficulttotreatdepressioniassociationwithchangeinqualityoflife
AT jiangmei alternativemetricsforcharacterizinglongertermclinicaloutcomesindifficulttotreatdepressioniassociationwithchangeinqualityoflife
AT badejosarah alternativemetricsforcharacterizinglongertermclinicaloutcomesindifficulttotreatdepressioniassociationwithchangeinqualityoflife
AT bunkermarkt alternativemetricsforcharacterizinglongertermclinicaloutcomesindifficulttotreatdepressioniassociationwithchangeinqualityoflife
AT aaronsonscottt alternativemetricsforcharacterizinglongertermclinicaloutcomesindifficulttotreatdepressioniassociationwithchangeinqualityoflife
AT conwaycharlesr alternativemetricsforcharacterizinglongertermclinicaloutcomesindifficulttotreatdepressioniassociationwithchangeinqualityoflife
AT demyttenaerekoen alternativemetricsforcharacterizinglongertermclinicaloutcomesindifficulttotreatdepressioniassociationwithchangeinqualityoflife
AT youngallanh alternativemetricsforcharacterizinglongertermclinicaloutcomesindifficulttotreatdepressioniassociationwithchangeinqualityoflife
AT mcallisterwilliamsrhamish alternativemetricsforcharacterizinglongertermclinicaloutcomesindifficulttotreatdepressioniassociationwithchangeinqualityoflife